Accelerating discovery science to clinical translation: CiC3 - The Oxford MRC CiC Pipeline
Lead Research Organisation:
University of Oxford
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
People |
ORCID iD |
Publications
Dean BJ
(2016)
The Effects of Glucocorticoid on Tendon and Tendon Derived Cells.
in Advances in experimental medicine and biology
Hakimi O
(2015)
A layered electrospun and woven surgical scaffold to enhance endogenous tendon repair.
in Acta biomaterialia
| Description | 'Frontiers of Science' A comparative study on diseases caused by the endemic and emerging viral agents Dengue, Chikungunya and Zika. |
| Amount | $4,000,000 (MXN) |
| Funding ID | Project No. 1192 |
| Organisation | National Council on Science and Technology (CONACYT) |
| Sector | Public |
| Country | Mexico |
| Start | 09/2016 |
| End | 08/2019 |
| Description | Action Duchenne translational research |
| Amount | £48,000 (GBP) |
| Organisation | Action Duchenne |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2015 |
| End | 02/2018 |
| Description | Anaptysbio Research Grant |
| Amount | £700,000 (GBP) |
| Organisation | AnaptysBio |
| Sector | Private |
| Country | United States |
| Start | 02/2017 |
| End | 01/2019 |
| Description | British Medical Association |
| Amount | £35,000 (GBP) |
| Organisation | British Medical Association (BMA) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2012 |
| End | 09/2014 |
| Description | British Skin Foundation Grant |
| Amount | £62,000 (GBP) |
| Organisation | British Skin Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 12/2014 |
| End | 12/2015 |
| Description | British Skin Foundation Large Research Awards |
| Amount | £70,000 (GBP) |
| Organisation | British Skin Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2008 |
| End | 09/2011 |
| Description | Cancer Immunology Project award |
| Amount | £287,000 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2016 |
| End | 03/2020 |
| Description | Celgene Fellowship |
| Amount | £500,000 (GBP) |
| Organisation | Bristol-Myers Squibb |
| Department | Celgene |
| Sector | Private |
| Country | United States |
| Start | 01/2016 |
| End | 01/2020 |
| Description | Clinical Biomanufacture of Nanofibre scaffolds for soft tissue repair |
| Amount | £75,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2015 |
| End | 05/2016 |
| Description | Comprehensive Research Network |
| Amount | £1,700,000 (GBP) |
| Organisation | National Institute for Health Research |
| Department | NIHR Clinical Research Network (CRN) |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 04/2007 |
| End | 03/2017 |
| Description | Confidence in Concept |
| Amount | £4,800 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2018 |
| End | 02/2018 |
| Description | Confidence in Concept (CiC) by MRC |
| Amount | £100,023 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2015 |
| End | 06/2016 |
| Description | Development of EVs for AAV vector muscle delivery |
| Amount | £150,000 (GBP) |
| Organisation | Muscular Dystrophy Association |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 09/2019 |
| End | 08/2021 |
| Description | Development of adenosine receptor modulators as treatment for circadin rhythm disorders |
| Amount | £450,000 (GBP) |
| Organisation | CIRCADIAN Therapeutics Ltd. |
| Sector | Private |
| Country | United Kingdom |
| Start | 01/2021 |
| End | 09/2022 |
| Description | Duchenne UK translational research |
| Amount | £50,000 (GBP) |
| Organisation | Duchenne UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2015 |
| End | 02/2018 |
| Description | EXPLORATORY/DEVELOPMENT GRANT |
| Amount | $137,000 (USD) |
| Funding ID | 1R21AI125886-01 |
| Organisation | National Institutes of Health (NIH) |
| Sector | Public |
| Country | United States |
| Start | 09/2016 |
| End | 08/2018 |
| Description | EvOx |
| Amount | £10,000,000 (GBP) |
| Organisation | EvOx Therapeutics |
| Sector | Private |
| Country | United Kingdom |
| Start | 05/2016 |
| End | 02/2018 |
| Description | Evox |
| Amount | £650,000 (GBP) |
| Organisation | EvOx Therapeutics |
| Sector | Private |
| Country | United Kingdom |
| Start | 01/2017 |
| End | 12/2018 |
| Description | Janssen collaborative research grant |
| Amount | $1,600,000 (USD) |
| Organisation | Johnson & Johnson |
| Department | Janssen Pharmaceuticals |
| Sector | Private |
| Country | United States |
| Start | 10/2013 |
| End | 09/2015 |
| Description | John Fell Fund |
| Amount | £14,970 (GBP) |
| Funding ID | 0006270 |
| Organisation | University of Oxford |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 01/2019 |
| End | 01/2020 |
| Description | Johnson and Johnson collaborative research |
| Amount | £100,000 (GBP) |
| Organisation | Johnson & Johnson |
| Sector | Private |
| Country | United States |
| Start | 01/2015 |
| End | 12/2015 |
| Description | MRC Experimental Medicine 2 |
| Amount | £380,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2009 |
| End | 09/2012 |
| Description | MRC/UCB Antibody Discovery Initiative |
| Amount | £250,000 (GBP) |
| Funding ID | MC_EX_MR/R022550/1 |
| Organisation | University of Oxford |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 02/2019 |
| End | 12/2019 |
| Description | NIHR Senioe Investigator |
| Amount | £60,000 (GBP) |
| Organisation | University of Leicester |
| Department | NIHR Biomedical Research Centre |
| Sector | Hospitals |
| Country | United Kingdom |
| Start | 04/2018 |
| End | 03/2022 |
| Description | New vaccines for global epidemics: development and manufacture |
| Amount | £488,611 (GBP) |
| Funding ID | TSB File Ref.: 972214. Application No. 71744-493192 |
| Organisation | SBRI Healthcare |
| Sector | Private |
| Country | United Kingdom |
| Start | 10/2016 |
| End | 09/2017 |
| Description | Oxford Biomedical Research Centre |
| Amount | £1,000,000 (GBP) |
| Organisation | Oxford University Hospitals NHS Foundation Trust |
| Department | NIHR Oxford Biomedical Research Centre |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 04/2007 |
| End | 03/2017 |
| Description | PepGen: Peptide platform |
| Amount | £68,000 (GBP) |
| Organisation | Charley's Fund |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 06/2017 |
| End | 01/2019 |
| Description | UCB Research grant |
| Amount | £354,000 (GBP) |
| Organisation | UCB Pharma |
| Sector | Private |
| Country | United Kingdom |
| Start | 09/2016 |
| End | 08/2018 |
| Description | Use of High-Definition immune profiling to understand mechanisms underpinning control of high-risk Human Papillomavirus (hrHPV) in exposed women |
| Amount | £15,000 (GBP) |
| Funding ID | CRUKDF 0119-JK |
| Organisation | University of Oxford |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 03/2019 |
| End | 03/2022 |
| Description | Wellcome Trust Collaboratiev Award |
| Amount | £3,000,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2018 |
| End | 04/2023 |
| Title | PBMC samples, serum and vaginal specimens from healthy women with exposure to high risk HPV |
| Description | Prospective longitudinal collection of PBMC samples, serum and self-taken vaginal swabs for DNA extraction and testing for high risk HPV obtained from women aged 16-55 with current or prior exposure - Ethics ref: 16/SW/0331. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2017 |
| Provided To Others? | No |
| Impact | PBMC samples are being tested for T cells specific for HPV sequences in our vaccine and circulating in the population. Vaginal samples are tested for high risk HPV DNA. Serum will be tested for HPV-specific neutralising antibodies at PHE reference laboratory. |
| Description | Development of a multi-genotype therapeutic vaccine for pre-invasive high risk human papillomavirus disease (hrHPV) |
| Organisation | Vaccitech Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Developed therapeutic HPV vaccines using chimpanzee adenovirus and MVA vectors to deliver a novel immunogen. |
| Collaborator Contribution | Provided know-how and finances to undertake pre-GMP work prior to manufacture of GMP lots for clinical trial. |
| Impact | This collaboration has led to a further collaboration on a first-in-human trial to evaluate our therapeutic HPV vaccines. |
| Start Year | 2017 |
| Description | License option taken by Roche ventana |
| Organisation | Ventana Systems Inc |
| Country | United States |
| Sector | Private |
| PI Contribution | License option taken by Roche ventana to develop our technology to a diagnostic test. |
| Collaborator Contribution | Roche Ventana will validate and obtain the necessary approvals to proceed towards a diagnostic test |
| Impact | License option |
| Start Year | 2017 |
| Description | Prime-boost Vaccine Study in Women with Low-grade Cervical HPV Lesions |
| Organisation | Vaccitech Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | We will perform the immunology assays to assess the secondary and exploratory endpoints in the clinical trial. |
| Collaborator Contribution | Vaccitech is sponsoring and executing the clinical trial. |
| Impact | No outcomes yet. Clinical trial has been delayed 1 year because of COVID. |
| Start Year | 2020 |
| Title | ANALYSIS OF T-CELL MONOTYPIA |
| Description | A method of investigating the monotypia of a population of T-cells comprising detecting expression of the T cell receptor beta chain constant region TRBC1 and TRBC2, and/or the T cell receptor gamma chain constant region TRGC1 and TRGC, in a population of T-cells. |
| IP Reference | WO2016051205 |
| Protection | Patent granted |
| Year Protection Granted | 2016 |
| Licensed | Yes |
| Impact | Option to license taken by Roche |
| Title | Adenosine receptor modulators |
| Description | We have developed a range of modulators to manage diseases associated with circadian rhythm disturbances. This could be of great utility in managing a multitude of orphan disorders associated with circadian rhythm disorders such as non-24 sleep wake disorder, advanced sleep phase syndrome and also other potential mainstream mood related disorders. Towards this we have identified a range of molecules and demonstrated their validity in a range of preclinical in vitro and in vivo models of the disease. |
| IP Reference | GB1606622.7 |
| Protection | Patent application published |
| Year Protection Granted | 2016 |
| Licensed | Yes |
| Impact | This has resulted in establishing a new spin out "circadian therapeutics" and we are now seeking protection internationally. |
| Title | BETA LACTAMASE INHIBITORS |
| Description | A compound which is a thienolate of formula (I) or a pharmaceutically acceptable salt thereof: (I) wherein R1, R3, Ring A1, n and Ring A2 are as defined herein, are found to be useful in inhibiting metallo-beta-lactamase and therefore in potentiating the activity of beta lactamase antibiotics. The compound can be used alone or in combination with a rhodanine of formula (II) or a pharmaceutically acceptable salt thereof: (II) wherein R3, Ring A1, n, Ring A2, L and Ring B are as defined herein. Treatment or prevention of bacterial infection in combination with beta-lactam antibiotic agents is also provided. |
| IP Reference | WO2016051133 |
| Protection | Patent granted |
| Year Protection Granted | 2016 |
| Licensed | No |
| Impact | N/A |
| Title | DENGUE VACCINES |
| Description | The invention relates to a protein comprising a plurality of conserved peptide sequences, or variants thereof, wherein at least one of the conserved sequences is conserved across all four dengue virus serotypes DENV-1, DENV-2, DENV-3 and DENV-4, and wherein the conserved sequences comprise at least part of a sequence of one or more non-structural proteins of the dengue virus serotypes. The invention further relates to associated peptides, compositions,nucleic acids, viral vectors, virus- like particles, use,prime boost vaccination kits, agents and methods. |
| IP Reference | WO2016181147 |
| Protection | Patent application published |
| Year Protection Granted | 2016 |
| Licensed | Commercial In Confidence |
| Impact | Dengue vaccine for commercialisation |
| Title | ELECTROSPUN FILAMENTS |
| Description | A method for producing a continuous filament from electrospun fibres uses a conducting collection surface that is an elongate, three-dimensional surface, such as a moving wire (2). An attractive electric field gradient is formed between the collection surface of the wire (2) and a source (16) of electrically charged fibres (14). The collection surface of the wire (2) is moving in a longitudinal direction relative to the source (16) of electrically charged fibres. The fibres are collected on the surface of the wire (2) so as to form a continuous filament (24). The filaments (24) can then be stretched and assembled into multifilament yarns which imitate the hierarchical structure of tissues such as tendons and ligaments. |
| IP Reference | WO2015040399 |
| Protection | Patent application published |
| Year Protection Granted | 2015 |
| Licensed | No |
| Impact | • Progress has been made with routes to commercialisation • We have been working with an external consultant Les Russell and have had meetings with potential investors |
| Title | HPV VACCINE |
| Description | The invention relates to a nucleic acid encoding a polypeptide comprising a plurality of conserved peptide sequences, or variants thereof, wherein the conserved sequences are conserved across one or more HPV genotypes 16, 18, 31, 52, 53, and 58; and wherein the polypeptide comprises a conserved peptide sequence of each of the HPV proteins E1, E2, E4, E5, E6, and E7; and associated vaccines, viral vectors, treatment and prophylaxis. |
| IP Reference | WO2019034887 |
| Protection | Patent application published |
| Year Protection Granted | 2019 |
| Licensed | Yes |
| Impact | None |
| Title | SCAFFOLD |
| Description | A scaffold for tissue repair or wound dressing comprising: a material layer;a polymer fibre layer; and an adhesive component between the material layer and the polymer fibre layer, wherein the adhesive component comprises material having a lower melting temperature (Tm) than the material layer and the polymer fibre layer. |
| IP Reference | WO2015049524 |
| Protection | Patent application published |
| Year Protection Granted | 2015 |
| Licensed | No |
| Impact | • Progress has been made with routes to commercialisation • We have been working with an external consultant Les Russell and have had meetings with potential investors |
| Company Name | Circadian Therapeutics |
| Description | Current pharmacological treatments have fundamental limitations in addressing the scale of sleep and circadian rhythm disruption. Circadian Therapeutics has developed novel drugs that aim to fill the void, providing fast, effective, and safe treatment to patients in need. |
| Year Established | 2016 |
| Impact | 4 employed people |
| Website | https://www.circadiantherapeutics.com |
| Company Name | Evox Therapeutics |
| Description | Exosome therapeutic technology company |
| Year Established | 2016 |
| Impact | Development of therapeutic exosome technology. Investment from Oxford Sciences Innovation |
| Website | http://www.evoxtherapeutics.com |
| Company Name | PepGen |
| Description | PepGen, a new Oxford University Innovation spin out company. |
| Year Established | 2018 |
| Impact | Co-development with a pharmaceutical company in order to develop a novel multi-exon skipping approach with high efficiency for all DMD patients. |
| Description | "Cut & Paste" - genome editing (Royal Institution Family Fun day) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Other audiences |
| Results and Impact | "Cut & Paste" - genome editing activities at the Royal Institution Family Fun day on 22nd February 2019. It comprised three activities explaining genome editing and its utilisation as a research tool |
| Year(s) Of Engagement Activity | 2019 |
| Description | "Understanding allergy - Itching, sneezing, wheezing" |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Schools |
| Results and Impact | Two 30 minute talks to 9/10 year students explaining the immune system and allergy. The talks were part of Wadham College Aspiration day 4th March 2019 - Academic taster session. |
| Year(s) Of Engagement Activity | 2019 |
| Description | Dementia Friends - Public Engagement Event |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | This was a regional event organised by Dementia Friendly Chipping Norton, including a Dementia Friends Information Session, a couple of short research talks, and a panel Q&A. I contributed a talk and was a panel member. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Industry engagement with Roche |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | Negotiations with Roche for the license |
| Year(s) Of Engagement Activity | 2021 |
| Description | Oxford biotech deals highlight stature of UK university spinouts |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | http://www.evoxtherapeutics.com/news/2016/5/11/oxford-biotech-deals-highlight-stature-of-uk-university-spinouts |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.evoxtherapeutics.com/news/2016/5/11/oxford-biotech-deals-highlight-stature-of-uk-universi... |
| Description | RB visit to University of Oxford |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Gave short presentation on my HPV vaccine programme with a view to exploring interest in future partnership / funding. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Science club at Freeland Primary School |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Schools |
| Results and Impact | Visit to Freeland Primary School on 14th January 2020 to carry out a 1h session comprising three activities with primary school students to explain DNA and genome editing. |
| Year(s) Of Engagement Activity | 2020 |
| Description | Seminar to OUHT Microbiology department |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | Gave an overview of research leading to my CRUK funded project, how this project would address significant knowledge gaps and what the Microbiology department would learn from our study. Also suggested ideas for collaborations with members of the department. |
| Year(s) Of Engagement Activity | 2017 |
| Description | T cell differentation |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Schools |
| Results and Impact | 1h session during Biology Summer School which took place at Wadham College on 21st August 2019. The activity looked at how naïve T cells differentiate into T cell subsets in vitro. |
| Year(s) Of Engagement Activity | 2019 |
| Description | The Immune Cell Highway |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Other audiences |
| Results and Impact | The Immune Cell Highway was a session organised for Superdads Playgroup at Northway Church, Oxford on 8th February 2020. The activities were aimed at explaining how immune cells move around the body via two pathways - the blood & the lymphatics - and how this travelling is essential for clearing infections in the skin. |
| Year(s) Of Engagement Activity | 2020 |
| Description | The Immune Cell Highway (Swindon Science Festival) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | The Immune Cell Highway activity links the work being done in the Dong, Ogg and Jackson labs in the WIMM. They have created a stand explaining how immune cells move around the body via two pathways: the blood & the lymphatics. This activity was part of Swindon Science Festival on 21st and 22nd February 2020. |
| Year(s) Of Engagement Activity | 2020 |
| Description | UKSF - Liverpool Research Training Day |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | The Stroke Research Training Day is aimed at those who want to get involved in research for the first time as well as those who have already started in a research career. Around 85 delegates attended. The training day combined presentations and expert coaching by the Stroke Association Lecturers. This interactive day set out a compelling case for stroke research, described the main studies going on right now, and looked at future horizons. We explored funding opportunities, the role of the Research Design Service and the critical role that people affected by stroke play in the research process. Hands on coaching sessions included: how to create a poster and give a talk; how to balance clinical and research interests; how to respond to peer review comments; choosing the right research methods. |
| Year(s) Of Engagement Activity | 2015,2016,2017 |
| URL | https://www.stroke.org.uk/uksf-conference |
| Description | Understanding allergy - Itching, sneezing, wheezing |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Schools |
| Results and Impact | Two 30 minute sessions doing an "allergy testing" experiment with 9/10 year students. These sessions were part of Wadham College Aspiration Day - Academic taster session on 10th May 2019. |
| Year(s) Of Engagement Activity | 2019 |